Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.31 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GALR3 | O60755 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698610 | 0.93 | ALDH1A1 (0.36) | KDM4CPARP1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4698844 | 0.93 | ROCK2 (0.34) | LMNAPARP1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4700349 | 0.89 | PARP1 (0.36) | PARP1ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4698872 | 0.85 | PARP1 (0.33) | PARP1ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4703627 | 0.82 | KMT2A (0.37) | PARP1ALDH1A1MEN1KMT2AROCK2 | |
| SCHEMBL4701832 | 0.82 | BDKRB2 (0.38) | GAALMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4698698 | 0.81 | PARP1 (0.37) | PARP1ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6389603 | 0.79 | MET (0.36) | LMNAALDH1A1KMT2AROCK2MAPT | |
| SCHEMBL6386247 | 0.78 | ALDH1A1 (0.37) | KDM4CGAALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4698835 | 0.77 | ROCK2 (0.36) | GAALMNAALDH1A1SMN1; SMN2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458684-B1 | THERAPEUTIC HETEROCYCLES AS BRADYKININ B2 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-16 | — | — | EP | claimed |
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | claimed |
| EP-1458684-A2 | THERAPEUTIC HETEROCYCLES | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003051276-A2 | THERAPEUTIC HETEROCYCLES | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | claimed |
| EP-1458684-B1 | THERAPEUTIC HETEROCYCLES AS BRADYKININ B2 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-16 | — | — | EP | disclosed |
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | KDM4C 1795/4885GAA 1270/4885LMNA 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.